FierceBiotech17h
Gilead's Daniel O'Day relishes Dietmar Berger reunion as cancer specialist agrees to join from Sanofi
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
ENDPOINTS NEWS15h
Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set
Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...
BioPharma Dive8h
Dietmar Berger is Gilead’s new CMO; Padlock investors sue Bristol Myers
Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...
The Pharma Letter14h
Gilead Sciences names new CMO
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...
GlobalData on MSN4d
Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint
Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...
pharmaphorum3d
Sanofi invests €300m in Orano Med's lead-based radioligands
Sanofi's chief medical officer Dietmar Berger has previously said that lead-212 has a "differentiated biophysical and clinical profile, reinforcing its potential to be a transformative ...
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...